Metoprolol succinate ER is a long-acting formulation of metoprolol, a beta-blocker medication used to treat various cardiovascular conditions.
What is Metoprolol Succinate ER prescribed for?
Metoprolol succinate ER is primarily prescribed for the treatment of hypertension (high blood pressure) and angina pectoris (chest pain due to reduced blood flow to the heart) [1]. It is also used to improve survival after a myocardial infarction (heart attack) [1].
How does Metoprolol Succinate ER work?
As a beta-blocker, metoprolol succinate ER works by blocking the effects of adrenaline (epinephrine) on the heart and blood vessels [1]. This slows the heart rate, reduces the force of heart contractions, and relaxes blood vessels, all of which contribute to lowering blood pressure and reducing the heart's workload. The "ER" in metoprolol succinate ER stands for extended-release, meaning the medication is designed to release slowly over time, providing a more consistent effect throughout the day [1].
When does Metoprolol Succinate ER patent protection end?
Patent information for specific drug formulations can be complex and vary by region. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals. For metoprolol succinate ER, specific patent expiry dates would need to be consulted on databases like DrugPatentWatch.com [2].
Are there generic versions of Metoprolol Succinate ER available?
Yes, generic versions of metoprolol succinate ER are available. The availability of generics typically begins after the expiration of primary patents and any associated exclusivities.
What is the difference between metoprolol succinate ER and metoprolol tartrate?
Metoprolol succinate and metoprolol tartrate are both forms of metoprolol, but they differ in their release mechanisms and dosing frequency. Metoprolol tartrate is an immediate-release formulation typically taken twice a day, while metoprolol succinate is an extended-release formulation designed for once-daily dosing [3]. This difference in release can affect how the drug is absorbed and its duration of action.
What are potential side effects of Metoprolol Succinate ER?
Common side effects of metoprolol succinate ER can include fatigue, dizziness, slow heart rate, shortness of breath, and cold hands or feet [1]. More serious side effects, though less common, can also occur [1].
Can Metoprolol Succinate ER be used in patients with heart failure?
Metoprolol succinate ER is indicated to improve survival in patients who have had a myocardial infarction, which often involves heart failure. It is generally used cautiously in patients with heart failure, and dosing is carefully managed [1].
What are the risks of stopping Metoprolol Succinate ER abruptly?
Stopping metoprolol succinate ER suddenly can lead to serious cardiovascular events, including worsening angina, heart attack, or irregular heart rhythms. It is crucial to consult a healthcare provider before discontinuing the medication [1].
How does Metoprolol Succinate ER compare to other beta-blockers?
Metoprolol succinate ER is a selective beta-1 blocker, meaning it primarily affects the heart. Other beta-blockers may be non-selective or have additional properties, making them suitable for different conditions or patient profiles. The choice of beta-blocker depends on the specific medical condition and individual patient factors [4].
Where can I find detailed patent information for Metoprolol Succinate ER?
Detailed patent information, including expiry dates and any associated litigation, for metoprolol succinate ER and other pharmaceuticals can be found on specialized databases such as DrugPatentWatch.com [2].
What clinical data supports the use of Metoprolol Succinate ER?
Clinical trials have demonstrated the efficacy of metoprolol succinate ER in reducing blood pressure, treating angina, and improving outcomes in post-myocardial infarction patients. For instance, the MERIT-HF study was a significant trial that established the benefit of metoprolol succinate in patients with heart failure [5].
Sources:
[1] https://www.nhs.uk/medicines/metoprolol/
[2] https://drugpatentwatch.com/
[3] https://www.drugs.com/mtm/metoprolol-succinate-extended-release-vs-metoprolol-tartrate.html
[4] https://www.ncbi.nlm.nih.gov/books/NBK534856/
[5] https://www.nejm.org/doi/full/10.1056/NEJM199907293410503